DOCK2

Overview

DOCK2 (Dedicator of Cytokinesis 2) encodes a RAC1 guanine nucleotide exchange factor (GEF) that dimerizes with ELMO1 to activate RAC1 signaling. In cancer, DOCK2 mutations disrupt ELMO1/DOCK2/RAC1-mediated cytoskeletal remodeling, promoting invasive behavior.

Alterations observed in the corpus

  • Significantly mutated in esophageal adenocarcinoma (EAC); two tumors carried two independent DOCK2 mutations each; ELMO1/DOCK2 pathway mutations increase NIH/3T3 cell invasion 2-7-fold in functional assays PMID:23525077

Cancer types (linked)

  • Esophageal adenocarcinoma: significantly mutated gene; functional assays demonstrate pro-invasive activity PMID:23525077

Co-occurrence and mutual exclusivity

  • DOCK2 mutations co-occur with ELMO1 mutations in EAC; both act upstream of RAC1 GTPase activation PMID:23525077

Therapeutic relevance

  • No direct therapeutic data in the corpus; RAC1/ELMO1/DOCK2 axis is a candidate therapeutic target in invasive EAC.

Open questions

  • Whether DOCK2 mutations drive invasion in vivo and whether DOCK2 loss-of-function or gain-of-function is the primary mechanism.

Sources

This page was processed by crosslinker on 2026-05-09.